Keep Up With Cancer

Oncology

The systems needed to deliver GBT testing consistently across the NHS are still evolving to keep pace with these scientific advances.

News

argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.